TCTR20230227002已完成2 期
Baricitinib for Prurigo nodularis: A pilot study on efficacy and safety
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 12
研究概览
简要总结
This pilot investigation underscores the potential of baricitinib in Prurigo nodularis treatment, offering rapid clinical responses. However, larger and longer randomized controlled trials are needed to ascertain the efficacy, durability, and safety of baricitinib in Prurigo nodularis treatment.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 75 Years（—）
- 性别
- All
入选标准
- •moderate to severe prurigo nodularis (>= 20 nodules) persist 6 months or more
排除标准
- •1.Chronic pruritus not from Prurigo nodularis
- •2.Have latent or active Tuberculosis, HBV infection, HCV infection, HIV infection
- •3.Have history of Myocardial infarction, Unstable ischemic heart disease
- •4.Have history of Heart failure within 12 weeks before enrollment
- •5.Have history of Stroke
- •6.Have history of Deep vein thrombosis or pulmonary thromboembolism
- •7.Have history of uncontrolled disease eg. uncontrolled infection, active cancer
- •8.Currently on systemic immunosuppressants within 4 weeks before enrollment
- •9.hemoglobin less than 10.0 g/dL, total white blood cell less than 2500 cells/uL, neutropenia less than 1200 cells/uL, lymphopenia less than 750 cells/uL, thrombocytopenia less than 100000 cells/uL
- •10.Prenant woman or planned pregnant
研究者
相似试验
尚未招募
不适用
Efficacy and Safety of Tofacitinib in Patients With Prurigo NodularisItchPrurigo NodularisNCT06201715Second Affiliated Hospital, School of Medicine, Zhejiang University24
已完成
2 期
Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT)Pigmented Villonodular SynovitisNCT01261429Centre Leon Berard50
进行中（未招募）
1 期
Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell LymphomaRecurrent Mantle Cell LymphomaNCT02159755National Cancer Institute (NCI)28
已完成
2 期
Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen PlanusCutaneous Lichen PlanusNCT05188521Aaron R. Mangold12
进行中（未招募）
2 期
Phase II proof of concept study of baricitinib in individuals who are considered at risk of developing inflammatory arthritis: ExISTInflammatory arthritisMusculoskeletal DiseasesISRCTN53678960niversity of Leeds58